Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

101.69 +0.91 (+0.90%)
Official Closing Price Updated: 7:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,275,981
Open 100.97
Bid (Size) 100.86 (1)
Ask (Size) 102.82 (1)
Prev. Close 100.78
Today's Range 100.54 - 101.97
52wk Range 93.25 - 115.69
Shares Outstanding 1,750,942,289
Dividend Yield 1.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking At Abbott Laboratories's Recent Unusual Options Activity
 
Via Benzinga
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Recent troubles won't stop these companies' long-term trajectories. 
Via The Motley Fool

Performance

YTD
-7.20%
-7.20%
1 Month
-8.13%
-8.13%
3 Month
+4.88%
+4.88%
6 Month
-5.41%
-5.41%
1 Year
-9.78%
-9.78%

More News

Read More
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
Via Benzinga
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Via MarketBeat
Exposures COVID-19 Product Safety
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Via Benzinga
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
Via Benzinga
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Via Benzinga
Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices
Via Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
Abbott Laboratories Unusual Options Activity For May 10
Via Benzinga
Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories
Via Benzinga
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks
Via InvestorPlace
Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest'
Via Benzinga
3 Dividend Stock Warning Signs That Could Portend Trouble
Via The Motley Fool
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Got $1,000? 2 Top Dividend Stocks to Buy Now
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Is Dexcom a Good Stock to Buy Now?
Via The Motley Fool
3 Stocks to Buy Before They Soar to New Heights in 2023
Via InvestorPlace
Why Abbott Laboratories Stock Looks Ridiculously Overpriced
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.